financial
financial

Valeant Pharmaceuticals to Acquire Obagi

Under the terms of the agreement, Valeant will acquire all the outstanding common stock of Obagi for $19.75 a share in cash, or $360 million.

financial/news
News from WWD
Newsletters

Sign upSign up for WWD and FN newsletters to receive daily headlines, breaking news alerts and weekly industry wrap-ups.

LatestPublications
getIsArchiveOnly= hasAccess=false hasArchiveAccess=false